Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00112645 · ClinicalTrials.gov registry record · Phase 1
Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors
A Phase 1 study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00112645 is a Phase 1 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT00112645, a Phase 1 study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: A peripheral stem cell, bone marrow, or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving busulfan and melphalan with or without antithymocyte globulin before transplant and cyclosporine with methylprednisolone or methotrexate after transplant may stop this from happening. PURPOSE: This phase I trial is studying the side effects of donor stem cell transplant in treating young patients with relapsed or refractory solid tumors.
Interventions
- DRUG melphalan
- DRUG methotrexate
- DRUG busulfan
- DRUG cyclosporine
- BIOLOGICAL anti-thymocyte globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-04 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00112645
The ClinicalTrials.gov registry entry for NCT00112645 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which melphalan is the first listed.
NCT00112645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00112645 about?
NCT00112645 is a clinical study titled "Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors". RATIONALE: A peripheral stem cell, bone marrow, or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving b...
What is the current status of trial NCT00112645?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2005-04. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00112645?
The interventions under investigation include: melphalan (DRUG), methotrexate (DRUG), busulfan (DRUG), cyclosporine (DRUG), anti-thymocyte globulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00112645?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.